Kisplyx

Lenvatinib, the active ingredient in Kisplyx, is a tyrosine kinase inhibitor presented as an oral tablet for oral administration. It is indicated for the treatment of several advanced solid tumours, such as differentiated thyroid carcinoma, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma, in adult patients.

GNH USA supplies Kisplyx as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to oncology centres, hospitals and pharmacies worldwide from its EU‑origin market. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before distribution.

Lenvatinib is a multi‑targeted tyrosine kinase inhibitor used in the management of several solid tumours. - Differentiated thyroid carcinoma: improves progression‑free survival in patients with radioactive‑iodine refractory disease. - Renal cell carcinoma: reduces tumour growth and extends overall survival in advanced clear‑cell RCC. - Hepatocellular carcinoma: delays disease progression in patients with unresectable HCC. - Endometrial carcinoma: provides disease control in advanced or recurrent endometrial cancer.

Lenvatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Hypertension: elevated blood pressure often requiring medication. - Diarrhoea: watery stools that may cause dehydration. - Fatigue: persistent tiredness affecting daily activities. - Nausea: feeling of sickness that can reduce appetite.

Serious or Rare Side Effects: - Hepatotoxicity: liver enzyme elevations or liver failure. - Cardiac failure: signs of reduced cardiac function such as dyspnoea and edema. - Gastrointestinal perforation: severe abdominal pain indicating possible perforation. - Severe haemorrhage: bleeding events including gastrointestinal or intracranial bleeding.

When prescribing Lenvatinib, clinicians should consider several precautionary measures to minimise risks. - Blood pressure monitoring: check baseline and regularly during therapy. - Liver function tests: assess hepatic enzymes before starting and periodically. - Cardiac assessment: evaluate cardiac history and monitor for signs of heart failure. - Proteinuria screening: perform urine analysis to detect protein loss. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture and light.

Lenvatinib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inducers: agents such as rifampicin can markedly reduce lenvatinib exposure. - Anticoagulants: concurrent use may increase risk of severe bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: drugs like ketoconazole may increase lenvatinib plasma levels. - Antihypertensive agents: may require dose adjustment due to additive blood‑pressure effects. - Diuretics: can exacerbate electrolyte disturbances when combined with lenvatinib.